Search Results - "Benhadji, Karim Adnane"

A phase 1, open-label, first-in-human study of TAS2940 in patients with advanced solid tumors by Rodon Ahnert, Jordi, Spigel, David R., Kremer, Jill, Jin, Leah, Benhadji, Karim Adnane, Gil, Maciej, Besse, Benjamin

“…TPS3165 Background: Aberrant expression and signaling of the ERBB family of receptor tyrosine kinases, including epidermal growth factor receptor (EGFR) and…”
Get full text

A phase Ib dose-escalation and cohort-expansion study of safety and activity of the transforming growth factor (TGF) β receptor I kinase inhibitor galunisertib plus the anti-PD-L1 antibody durvalumab in metastatic pancreatic cancer by Melisi, Davide, Hollebecque, Antoine, Oh, Do-Youn, Calvo, Emiliano, Varghese, Anna M., Borazanci, Erkut Hasan, Mercade, Teresa Macarulla, Simionato, Francesca, Park, Joon Oh, Bendell, Johanna C., Faivre, Sandrine J., Zhao, Yumin, Gueorguieva, Ivelina, Man, Michael, Estrem, Shawn, Benhadji, Karim Adnane, Lanasa, Mark, Guba, Susan C., Garcia-Carbonero, Rocio

“…Abstract only 4124 Background: Pancreatic cancer (PC) is characterized by a highly immunosuppressive microenvironment, and immune checkpoint inhibitors as…”
Get full text

Phase I and pharmacokinetic (PK)/pharmacodynamic (PD) study of LY2334737, an oral gemcitabine prodrug, in patients (pts) with advanced solid tumors by Faivre, Sandrine J., Olszanski, Anthony J., Weigang-Koehler, Karin, Riess, Hanno, Peng, Guangbin, Callies, Sophie, Benhadji, Karim Adnane, Raymond, Eric

“…Abstract only 2554 Background: LY2334737 is a valproic acid-bound carboxylesterase-substrate prodrug of gemcitabine that can be given orally. The primary…”
Get full text

First-in-human phase I study of LY2780301, an oral P70S6K/AKT inhibitor, in patients with refractory solid tumors by Calvo, Emiliano, Benhadji, Karim Adnane, Azaro, Analia, Duran, Ignacio, Argiles, Guillem, Boni, Valentina, Ohnmacht, Ute, Wallin, Johan, Bumgardner, William Mark, Rodon Ahnert, Jordi

“…Abstract only 3005 Background: LY2780301is an oral potent, highly selective ATP competitive inhibitor against p70S6 kinase and AKT. We report on safety,…”
Get full text